Literature DB >> 6941373

Interactions of cimetidine and pirenzepine on peptone-stimulated gastric acid secretion in man.

W Londong, V Londong, R Prechtl, T Weber, K von Werder.   

Abstract

Combinations of H2-receptor antagonists and classical anticholinergics inhibit stimulated gastric acid secretion more than either drug alone. In double blind, placebo controlled, randomised studies we have compared the effects of single and combined intravenous bolus injections of cimetidine and pirenzepine on peptone-stimulated acid secretion and serum gastrin in man. Combined injection of 3.0 mg/kg cimetidine and 0.3 mg/kg pirenzepine suppressed stimulated acid secretion significantly more than either drug alone, and by 90% in healthy volunteers (n = 8) and patients with duodenal ulcer (n = 5). Side-effects (prolactin stimulation, blurred vision) were diminished by reducing the combined dosages to 1.5 mg/kg cimetidine, to 0.075 and 0.15 mg/kg pirenzepine in another series (n = 10). Postprandial gastrin was not affected by any combination. Combination of cimetidine and pirenzepine suppress food-stimulated gastric secretion more effectively than combination of H2-blockers with classical anticholinergics. Pirenzepine--unlike classical anticholinergics--may distinguish between different subclasses of muscarinic receptors and have a more selective antimuscarinic action. Its interaction with H2-receptor antagonists on parietal cell function seems to be synergistic. Such a combination could be of advantage in patients with gastrinoma, in patients with ulcers and hypersecretion resistant to single drug treatment, and in critically ill patients as prophylaxis of stress ulcer bleeding.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6941373

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

1.  Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine.

Authors:  W Londong; V Londong; C Federle; P Tanswell; U Voderholzer
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration.

Authors:  J G Williams; M Deakin; J K Ramage
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

3.  Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.

Authors:  V Savarino; P Scalabrini; G S Mela; E di Timoteo; G Percario; M R Magnolia; G Celle
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

Review 4.  Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs.

Authors:  L B Katz; T Genna; G H Greeley; D A Shriver
Journal:  Dig Dis Sci       Date:  1987-11       Impact factor: 3.199

5.  Combined anti-muscarinic and H2 receptor blockade in the healing of refractory duodenal ulcer. A double blind study.

Authors:  K D Bardhan; M Thompson; K Bose; R F Hinchliffe; J Crowe; D G Weir; C McCarthy; J Walters; T J Thomson; M H Thompson
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

6.  Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine.

Authors:  W Londong; V Londong; C Ruthe; P Weizert
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

7.  Telenzepine is at least 25 times more potent than pirenzepine--a dose response and comparative secretory study in man.

Authors:  W Londong; V Londong; A Meierl; U Voderholzer
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

Review 8.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.